Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 243

1.
2.

Differential effects of therapeutic complement Inhibitors on serum bactericidal activity against nongroupable meningococcal isolates recovered from patients treated with eculizumab.

Granoff DM, Kim H, Topaz N, MacNeil J, Wang X, McNamara LA.

Haematologica. 2019 Jan 31. pii: haematol.2018.209692. doi: 10.3324/haematol.2018.209692. [Epub ahead of print]

3.

A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.

Beernink PT, Ispasanie E, Lewis LA, Ram S, Moe GR, Granoff DM.

J Infect Dis. 2019 Mar 15;219(7):1130-1137. doi: 10.1093/infdis/jiy609.

PMID:
30346576
4.

Fatal Nongroupable Neisseria meningitidis Disease in Vaccinated Patient Receiving Eculizumab.

Nolfi-Donegan D, Konar M, Vianzon V, MacNeil J, Cooper J, Lurie P, Sedivy J, Wang X, Granoff DM, McNamara L.

Emerg Infect Dis. 2018 Aug;24(8). doi: 10.3201/eid2408.180228.

5.

The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.

Partridge E, Lujan E, Giuntini S, Vu DM, Granoff DM.

Vaccine. 2017 Jul 24;35(33):4236-4244. doi: 10.1016/j.vaccine.2017.06.020. Epub 2017 Jun 23.

6.

Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults.

Konar M, Granoff DM.

Blood. 2017 Aug 17;130(7):891-899. doi: 10.1182/blood-2017-05-781450. Epub 2017 Jun 19.

7.

Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.

Lujan E, Winter K, Rovaris J, Liu Q, Granoff DM.

Clin Infect Dis. 2017 Oct 1;65(7):1112-1119. doi: 10.1093/cid/cix519.

8.

Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.

Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM.

Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00121-17. doi: 10.1128/CVI.00121-17. Print 2017 Aug.

9.

Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.

Giuntini S, Lujan E, Gibani MM, Dold C, Rollier CS, Pollard AJ, Granoff DM.

Clin Vaccine Immunol. 2017 Jan 5;24(1). pii: e00430-16. doi: 10.1128/CVI.00430-16. Print 2017 Jan.

10.

Meningococcal B Vaccine during a University Outbreak.

Granoff DM.

N Engl J Med. 2016 Oct 20;375(16):1594. doi: 10.1056/NEJMc1610666. No abstract available.

PMID:
27797311
11.

Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Granoff DM, Giuntini S, Gowans FA, Lujan E, Sharkey K, Beernink PT.

JCI Insight. 2016 Sep 8;1(14):e88907. doi: 10.1172/jci.insight.88907.

12.

Human IgG1, IgG3, and IgG3 Hinge-Truncated Mutants Show Different Protection Capabilities against Meningococci Depending on the Target Antigen and Epitope Specificity.

Giuntini S, Granoff DM, Beernink PT, Ihle O, Bratlie D, Michaelsen TE.

Clin Vaccine Immunol. 2016 Aug 5;23(8):698-706. doi: 10.1128/CVI.00193-16. Print 2016 Aug.

13.
14.

Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.

Lujan E, Pajon R, Granoff DM.

Infect Immun. 2015 Nov 23;84(2):452-8. doi: 10.1128/IAI.01267-15. Print 2016 Feb.

15.

Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Giuntini S, Beernink PT, Granoff DM.

Vaccine. 2015 Dec 16;33(51):7168-7175. doi: 10.1016/j.vaccine.2015.10.135. Epub 2015 Nov 10.

16.

Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Rossi R, Beernink PT, Giuntini S, Granoff DM.

Clin Vaccine Immunol. 2015 Dec;22(12):1227-34. doi: 10.1128/CVI.00474-15. Epub 2015 Sep 30.

17.

A Newly-Identified Polymorphism in Rhesus Macaque Complement Factor H Modulates Binding Affinity for Meningococcal FHbp.

Konar M, Beernink PT, Granoff DM.

PLoS One. 2015 Aug 18;10(8):e0135996. doi: 10.1371/journal.pone.0135996. eCollection 2015.

18.

Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein.

Beernink PT, Giuntini S, Costa I, Lucas AH, Granoff DM.

MBio. 2015 Jun 23;6(3):e00842. doi: 10.1128/mBio.00842-15.

19.

Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Granoff DM, Costa I, Konar M, Giuntini S, Van Rompay KK, Beernink PT.

J Infect Dis. 2015 Sep 1;212(5):784-92. doi: 10.1093/infdis/jiv081. Epub 2015 Feb 12.

20.

A native outer membrane vesicle vaccine confers protection against meningococcal colonization in human CEACAM1 transgenic mice.

Pajon R, Buckwalter CM, Johswich KO, Gray-Owen SD, Granoff DM.

Vaccine. 2015 Mar 10;33(11):1317-1323. doi: 10.1016/j.vaccine.2015.01.057. Epub 2015 Feb 4.

21.

Binding of complement factor H to PorB3 and NspA enhances resistance of Neisseria meningitidis to anti-factor H binding protein bactericidal activity.

Giuntini S, Pajon R, Ram S, Granoff DM.

Infect Immun. 2015 Apr;83(4):1536-45. doi: 10.1128/IAI.02984-14. Epub 2015 Feb 2.

22.

Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Beernink PT, Shaughnessy J, Stefek H, Ram S, Granoff DM.

Clin Vaccine Immunol. 2014 Nov;21(11):1505-11. doi: 10.1128/CVI.00517-14. Epub 2014 Sep 3.

23.

Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.

Costa I, Pajon R, Granoff DM.

MBio. 2014 Aug 26;5(5):e01625-14. doi: 10.1128/mBio.01625-14.

24.

Fusion protein comprising factor H domains 6 and 7 and human IgG1 Fc as an antibacterial immunotherapeutic.

Shaughnessy J, Vu DM, Punjabi R, Serra-Pladevall J, DeOliveira RB, Granoff DM, Ram S.

Clin Vaccine Immunol. 2014 Oct;21(10):1452-9. doi: 10.1128/CVI.00444-14. Epub 2014 Aug 20.

25.

Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Lewis LA, Vu DM, Granoff DM, Ram S.

Infect Immun. 2014 Jun;82(6):2574-84. doi: 10.1128/IAI.01517-14. Epub 2014 Mar 31.

26.

Factor H-dependent alternative pathway inhibition mediated by porin B contributes to virulence of Neisseria meningitidis.

Lewis LA, Vu DM, Vasudhev S, Shaughnessy J, Granoff DM, Ram S.

MBio. 2013 Oct 15;4(5):e00339-13. doi: 10.1128/mBio.00339-13.

27.

Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.

Rossi R, Granoff DM, Beernink PT.

Vaccine. 2013 Nov 4;31(46):5451-7. doi: 10.1016/j.vaccine.2013.08.099. Epub 2013 Sep 11.

28.

Portrait: coincidences, convergences and opportunities.

Granoff DM.

Hum Vaccin Immunother. 2013 May;9(5):945-9. doi: 10.4161/hv.25151. Epub 2013 Aug 21.

29.

Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa.

Pajon R, Fergus AM, Granoff DM.

PLoS One. 2013 Jun 21;8(6):e66536. doi: 10.1371/journal.pone.0066536. Print 2013.

30.

fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.

Giuntini S, Vu DM, Granoff DM.

Vaccine. 2013 Aug 28;31(38):4192-9. doi: 10.1016/j.vaccine.2013.06.009. Epub 2013 Jun 17.

31.

Does binding of complement factor H to the meningococcal vaccine antigen, factor H binding protein, decrease protective serum antibody responses?

Granoff DM, Ram S, Beernink PT.

Clin Vaccine Immunol. 2013 Aug;20(8):1099-107. doi: 10.1128/CVI.00260-13. Epub 2013 Jun 5. Review.

32.

Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Konar M, Granoff DM, Beernink PT.

J Infect Dis. 2013 Aug 15;208(4):627-36. doi: 10.1093/infdis/jit239. Epub 2013 May 28.

33.

Commentary: European Medicines Agency recommends approval of a broadly protective vaccine against serogroup B meningococcal disease.

Granoff DM.

Pediatr Infect Dis J. 2013 Apr;32(4):372-3. doi: 10.1097/INF.0b013e318282942f. No abstract available.

PMID:
23263177
34.

Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.

Pajon R, Beernink PT, Granoff DM.

Infect Immun. 2012 Aug;80(8):2667-77. doi: 10.1128/IAI.00103-12. Epub 2012 May 21. Erratum in: Infect Immun. 2014 Apr;82(4):1742.

35.

The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Beernink PT, Shaughnessy J, Pajon R, Braga EM, Ram S, Granoff DM.

PLoS Pathog. 2012;8(5):e1002688. doi: 10.1371/journal.ppat.1002688. Epub 2012 May 10.

36.

A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp.

Vu DM, Pajon R, Reason DC, Granoff DM.

Sci Rep. 2012;2:341. doi: 10.1038/srep00341. Epub 2012 Mar 28. Erratum in: Sci Rep. 2013 Mar 20;3. doi:10.1038/srep01499.

37.

Monoclonal antibodies to meningococcal factor H binding protein with overlapping epitopes and discordant functional activity.

Giuntini S, Beernink PT, Reason DC, Granoff DM.

PLoS One. 2012;7(3):e34272. doi: 10.1371/journal.pone.0034272. Epub 2012 Mar 26.

38.

Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidis.

Vu DM, Shaughnessy J, Lewis LA, Ram S, Rice PA, Granoff DM.

Infect Immun. 2012 Feb;80(2):643-50. doi: 10.1128/IAI.05604-11. Epub 2011 Nov 21.

39.
40.

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development.

Pajon R, Fergus AM, Koeberling O, Caugant DA, Granoff DM.

PLoS Negl Trop Dis. 2011 Sep;5(9):e1302. doi: 10.1371/journal.pntd.0001302. Epub 2011 Sep 6.

41.

Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding.

Giuntini S, Reason DC, Granoff DM.

Infect Immun. 2011 Sep;79(9):3751-9. doi: 10.1128/IAI.05182-11. Epub 2011 Jun 27.

42.

Immunogenicity of a meningococcal native outer membrane vesicle vaccine with attenuated endotoxin and over-expressed factor H binding protein in infant rhesus monkeys.

Koeberling O, Seubert A, Santos G, Colaprico A, Ugozzoli M, Donnelly J, Granoff DM.

Vaccine. 2011 Jun 24;29(29-30):4728-34. doi: 10.1016/j.vaccine.2011.04.095. Epub 2011 May 13.

43.
44.

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination.

Beernink PT, Shaughnessy J, Braga EM, Liu Q, Rice PA, Ram S, Granoff DM.

J Immunol. 2011 Mar 15;186(6):3606-14. doi: 10.4049/jimmunol.1003470. Epub 2011 Feb 16.

45.

Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen.

Vu DM, Wong TT, Granoff DM.

Vaccine. 2011 Feb 24;29(10):1968-73. doi: 10.1016/j.vaccine.2010.12.075. Epub 2011 Jan 15.

46.

Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood.

Dunphy KY, Beernink PT, Brogioni B, Granoff DM.

Infect Immun. 2011 Jan;79(1):353-9. doi: 10.1128/IAI.00849-10. Epub 2010 Nov 1.

47.

Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding.

Beernink PT, Shaughnessy J, Ram S, Granoff DM.

Clin Vaccine Immunol. 2010 Jul;17(7):1074-8. doi: 10.1128/CVI.00103-10. Epub 2010 Jun 2.

48.

Review of meningococcal group B vaccines.

Granoff DM.

Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S54-65. doi: 10.1086/648966. Review.

49.

Frequency of factor H-binding protein modular groups and susceptibility to cross-reactive bactericidal activity in invasive meningococcal isolates.

Pajon R, Beernink PT, Harrison LH, Granoff DM.

Vaccine. 2010 Feb 25;28(9):2122-9. doi: 10.1016/j.vaccine.2009.12.027. Epub 2009 Dec 29.

50.

The modular architecture of meningococcal factor H-binding protein.

Beernink PT, Granoff DM.

Microbiology. 2009 Sep;155(Pt 9):2873-83. doi: 10.1099/mic.0.029876-0. Epub 2009 Jul 2.

Supplemental Content

Loading ...
Support Center